Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Search
HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US
See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month
New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease
Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease
Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US
Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
OFEV® (nintedanib) Now Available in the United States
OFEV® (nintedanib) Now Available in the United States
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
Real-world study shows sequencing of Gilotrif